Does neuroimmune dysfunction mediate seasonal mood changes in winter depression?

Medical Hypotheses

Volumn 63, Issue 4, 2004, Pages 567-573

  Lam, Raymond W ^a,b   Song, Cai ^a,b   Yatham, Lakshmi N ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; MELATONIN; NEUROTRANSMITTER;

CORRELATION ANALYSIS; DIAGNOSTIC TEST; HUMAN; HYPOTHESIS; IMMUNE DEFICIENCY; IMMUNE SYSTEM; MEDICAL RESEARCH; PHOTOPERIODICITY; PRIORITY JOURNAL; REVIEW; SEASONAL AFFECTIVE DISORDER; SUMMER; WINTER;

ANIMALIA;

EID: 8444222668     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.03.024     Document Type: Article

References (85)

1. Bartness T.J., Goldman B.D. Mammalian pineal melatonin: a clock for all seasons. Experientia. 45:1989;939-945
2. Reiter R.J. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr. Rev. 12:1991;151-180
3. Lewy A.J., Wehr T.A., Goodwin F.K., Newsome D.A., Markey S.P. Light suppresses melatonin secretion in humans. Science. 210:1980;1267-1269
4. Wehr T.A. Melatonin and seasonal rhythms [see comments]. J. Biol. Rhythms. 12:1997;518-527
5. Nelson R.J., Demas G.E. Seasonal changes in immune function. Q. Rev. Biol. 71:1996;511-548
6. Nelson R.J., Demas G.E. Role of melatonin in mediating seasonal energetic and immunologic adaptations. Brain Res. Bull. 44:1997;423-430
7. Nelson R.J., Demas G.E., Klein S.L., Kriegsfeld L.J. Seasonal patterns of stress, immune function, & disease. 2002;Cambridge University Press, Cambridge, UK
8. Nelson R.J., Drazen D.L. Melatonin mediates seasonal changes in immune function. Ann. NY Acad. Sci. 917:2000;404-415
9. Maestroni G.J. The immunoneuroendocrine role of melatonin. J. Pineal Res. 14:1993;1-10
10. Calvo J.R., Rafii-el-Idrissi M., Pozo D., Guerrero J.M. Immunomodulatory role of melatonin: specific binding sites in human and rodent lymphoid cells. J. Pineal Res. 18:1995;119-126
11. 125I]iodomelatonin binding sites in spleens of guinea pigs. Life Sci. 50:1992;1719-1726
12. Pang C.S., Brown G.M., Tang P.L., Cheng K.M., Pang S.F. 2-[125I]iodomelatonin binding sites in the lung and heart: a link between the photoperiodic signal, melatonin, and the cardiopulmonary system. Biol. Signals. 2:1993;228-236
13. Lopez-Gonzalez M.A., Calvo J.R., Osuna C., Guerrero J.M. Interaction of melatonin with human lymphocytes: evidence for binding sites coupled to potentiation of cyclic AMP stimulated by vasoactive intestinal peptide and activation of cyclic GMP. J. Pineal Res. 12:1992;97-104
14. Wei W., Ding C.H., Xu S.Y. Effect of pineal body and melatonin on chemiluminescence of peritoneal macrophages via hypothalamus in rats. Zhongguo Yao Li Xue Bao. 16:1995;435-437
15. Shafer L.L., McNulty J.A., Young M.R. Assessment of melatonin's ability to regulate cytokine production by macrophage and microglia cell types. J. Neuroimmunol. 120:2001;84-93
16. Liu F., Ng T.B., Fung M.C. Pineal indoles stimulate the gene expression of immunomodulating cytokines. J. Neural. Transm. 108:2001;397-405
17. Haldar C., Singh R. Pineal modulation of thymus and immune function in a seasonally breeding tropical rodent, Funambulus pennanti. J. Exp. Zool. 289:2001;90-98
18. Rodriguez A.B., Lea R.W. Effect of pinealectomy upon the nonspecific immune response of the ring-dove (Streptopelia risoria). J. Pineal Res. 16:1994;159-166
19. del Gobbo V., Libri V., Villani N., Calio R., Nistico G. Pinealectomy inhibits interleukin-2 production and natural killer activity in mice. Int. J. Immunopharmacol. 11:1989;567-573
20. Garcia-Maurino S., Gonzalez-Haba M.G., Calvo J.R., Rafii-el-Idrissi M., Sanchez-Margalet V., Goberna R., et al. Melatonin enhances IL-2, IL-6, and IFN-gamma production by human circulating CD4+ cells: a possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes. J. Immunol. 159:1997;574-581
21. Lissoni P. Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and the other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasms. Ann. NY Acad. Sci. 917:2000;560-567
22. Kuhlwein E., Irwin M. Melatonin modulation of lymphocyte proliferation and Th1/Th2 cytokine expression. J. Neuroimmunol. 117:2001;51-57
23. Katila H., Cantell K., Appelberg B., Rimon R. Is there a seasonal variation in the interferon-producing capacity of healthy subjects? J. Interferon Res. 13:1993;233-234
24. Shearer W.T., Lee B.N., Cron S.G., Rosenblatt H.M., Smith E.O., Lugg D.J., et al. Suppression of human anti-inflammatory plasma cytokines IL-10 and IL-1RA with elevation of proinflammatory cytokine IFN-gamma during the isolation of the Antarctic winter. J. Allergy Clin. Immunol. 109:2002;854-857
25. Maes M., Stevens W., Scharpe S., Bosmans E., De Meyer F., D'Hondt P., et al. Seasonal variation in peripheral blood leukocyte subsets and in serum interleukin-6, and soluble interleukin-2 and -6 receptor concentrations in normal volunteers. Experientia. 50:1994;821-829
26. Lam R.W., Levitan R.D. Pathophysiology of seasonal affective disorder: a review. J. Psychiatry Neurosci. 25:2000;469-480
27. Rosenthal N.E., Sack D.A., Gillin J.C., Lewy A.J., Goodwin F.K., Davenport Y., et al. Seasonal affective disorder: a description of the syndrome and preliminary findings with light therapy. Arch. Gen. Psychiatry. 41:1984;72-80
28. Rosenthal N.E., Sack D.A., Jacobsen F.M., James S.P., Parry B.L., Arendt J., et al. Melatonin in seasonal affective disorder and phototherapy. J. Neural. Transm. Suppl. 21:1986;257-267
29. Isaacs G., Stainer D.S., Sensky T.E., Moor S., Thompson C. Phototherapy and its mechanisms of action in seasonal affective disorder. J. Affect. Disord. 14:1988;13-19
30. Wehr T.A., Jacobsen F.M., Sack D.A., Arendt J., Tamarkin L., Rosenthal N.E. Phototherapy of seasonal affective disorder. Time of day and suppression of melatonin are not critical for antidepressant effects. Arch. Gen. Psychiatry. 43:1986;870-875
31. Rosenthal N.E., Jacobsen F.M., Sack D.A., Arendt J., James S.P., Parry B.L., et al. Atenolol in seasonal affective disorder: a test of the melatonin hypothesis. Am. J. Psychiatry. 145:1988;52-56
32. Wehr T.A., Giesen H.A., Moul D.E., Turner E.H., Schwartz P.J. Suppression of men's responses to seasonal changes in day length by modern artificial lighting. Am. J. Physiol. 269:1995;R173-R178
33. Wehr T.A. Melatonin and seasonal rhythms. J. Biol. Rhythms. 12:1997;518-527
34. Wehr T.A. Effect of seasonal changes in daylength on human neuroendocrine function. Horm. Res. 49:1998;118-124
35. Wehr T.A., Duncan W.C. Jr., Sher L., Aeschbach D., Schwartz P.J., Turner E.H., et al. A circadian signal of change of season in patients with seasonal affective disorder. Arch. Gen. Psychiatry. 58:2001;1108-1114
36. Wehr T.A. Photoperiodism in humans and other primates: evidence and implications. J. Biol. Rhythms. 16:2001;348-364
37. Mersch P.P., Middendorp H.M., Bouhuys A.L., Beersma D.G., van den Hoofdakker R.H. Seasonal affective disorder and latitude: a review of the literature. J. Affect. Disord. 53:1999;35-48
38. Michalak E.E., Lam R. Seasonal affective disorder: the latitude hypothesis revisited. Can. J. Psychiatry. 47:2002;339-340
39. Albert P.S., Rosen L.N., Alexander J.R. Jr., Rosenthal N.E. Effect of daily variation in weather and sleep on seasonal affective disorder. Psychiatry Res. 36:1991;51-63
40. Lee T.M., Blashko C.A., Janzen H.L., Paterson J.G., Chan C.C. Pathophysiological mechanism of seasonal affective disorder. J. Affect. Disord. 46:1997;25-38
41. Danilenko K.V., Putilov A.A., Russkikh G.S., Duffy L.K., Ebbesson S.O. Diurnal and seasonal variations of melatonin and serotonin in women with seasonal affective disorder. Arctic Med. Res. 53:1994;137-145
42. Karadottir R., Axelsson J. Melatonin secretion in SAD patients and healthy subjects matched with respect to age and sex. Int. J. Circumpolar Health. 60:2001;548-551
43. Checkley S.A., Murphy D.G., Abbas M., Marks M., Winton F., Palazidou E., et al. Melatonin rhythms in seasonal affective disorder. Br. J. Psychiatry. 163:1993;332-337
44. Schlager D.S. Early-morning administration of short-acting beta blockers for treatment of winter depression. Am. J. Psychiatry. 151:1994;1383-1385
45. Salinas E.O., Hakim-Kreis C.M., Piketty M.L., Dardennes R.M., Musa C.Z. Hypersecretion of melatonin following diurnal exposure to bright light in seasonal affective disorder: preliminary results. Biol. Psychiatry. 32:1992;387-398
46. Thalen B.E., Kjellman B.F., Morkrid L., Wetterberg L. Melatonin in light treatment of patients with seasonal and nonseasonal depression. Acta Psychiatr. Scand. 92:1995;274-284
47. Childs P.A., Rodin I., Martin N.J., Allen N.H., Plaskett L., Smythe P.J., et al. Effect of fluoxetine on melatonin in patients with seasonal affective disorder and matched controls. Br. J. Psychiatry. 166:1995;196-198
48. Schwartz P.J., Turner E.H., Garcia-Borreguero D., Sedway J., Vetticad R.G., Wehr T.A., et al. Serotonin hypothesis of winter depression: behavioral and neuroendocrine effects of the 5-HT (1A) receptor partial agonist ipsapirone in patients with seasonal affective disorder and healthy control subjects. Psychiatry Res. 86:1999;9-28
49. Oren D.A., Levendosky A.A., Kasper S., Duncan C.C., Rosenthal N.E. Circadian profiles of cortisol, prolactin, and thyrotropin in seasonal affective disorder. Biol. Psychiatry. 39:1996;157-170
50. James S.P., Wehr T.A., Sack D.A., Parry B.L., Rogers S., Rosenthal N.E. The dexamethasone suppression test in seasonal affective disorder. Compr. Psychiatry. 27:1986;224-226
51. Gold P.W., Licinio J., Wong M.L., Chrousos G.P. Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Ann. NY Acad. Sci. 771:1995;716-729
52. Joseph-Vanderpool J.R., Rosenthal N.E., Chrousos G.P., Wehr T.A., Skwerer R., Kasper S., et al. Abnormal pituitary-adrenal responses to corticotropin-releasing hormone in patients with seasonal affective disorder: clinical and pathophysiological implications. J. Clin. Endocrinol. Metab. 72:1991;1382-1387
53. Khan R., Daya S., Potgieter B. Evidence for a modulation of the stress response by the pineal gland. Experientia. 46:1990;860-862
54. Jones M.T., Hillhouse E.W., Burden J. Effect on various putative neurotransmitters on the secretion of corticotrophin-releasing hormone from the rat hypothalamus in vitro-a model of the neurotransmitters involved. J. Endocrinol. 69:1976;1-10
55. Beck-Friis J., Kjellman B.F., Aperia B., et al. Serum melatonin in relation to clinical measures in patients with major affective disorders and a hypothesis of low melatonin syndrome. Acta Psychiatr. Scand. 71:1985;319-330
56. Konakchieva R., Mitev Y., Almeida O.F., Patchev V.K. Chronic melatonin treatment and the hypothalamo-pituitary-adrenal axis in the rat: attenuation of the secretory response to stress and effects on hypothalamic neuropeptide content and release. Biol. Cell. 89:1997;587-596
57. Konakchieva R., Mitev Y., Almeida O.F., Patchev V.K. Chronic melatonin treatment counteracts glucocorticoid-induced dysregulation of the hypothalamic-pituitary-adrenal axis in the rat. Neuroendocrinology. 67:1998;171-180
58. Marinova C., Persengiev S., Konakchieva R., Ilieva A., Patchev V. Melatonin effects on glucocorticoid receptors in rat brain and pituitary: significance in adrenocortical regulation. Int. J. Biochem. 23:1991;479-481
59. Leu S.J., Shiah I.S., Yatham L.N., Cheu Y.M., Lam R.W. Immune-inflammatory markers in patients with seasonal affective disorder: effects of light therapy. J. Affect. Disord. 63:2001;27-34
60. Nance D.M., Hopkins D.A., Bieger D. Re-investigation of the innervation of the thymus gland in mice and rats. Brain Behav. Immun. 1:1987;134-147
61. Elenkov I.J., Wilder R.L., Chrousos G.P., Vizi E.S. The sympathetic nerve - an integrative interface between two supersystems: the brain and the immune system. Pharmacol. Rev. 52:2000;595-638
62. Farrar W.L., Ferris D.K., Harel-Bellan A. The molecular basis of immune cytokine action. Crit. Rev. Ther. Drug Carrier Syst. 5:1989;229-261
63. Takao T., Tracey D.E., Mitchell W.M., De Souza E.B. Interleukin-1 receptors in mouse brain: characterization and neuronal localization. Endocrinology. 127:1990;3070-3078
64. Connor T.J., Leonard B.E. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci. 62:1998;583-606
65. Plata-Salaman C.R., Ilyin S.E. Interleukin-1beta (IL-1beta)-induced modulation of the hypothalamic IL-1beta system, tumor necrosis factor-alpha, and transforming growth factor-beta1 mRNAs in obese (fa/fa) and lean (Fa/Fa) Zucker rats: implications to IL-1beta feedback systems and cytokine-cytokine interactions. J. Neurosci. Res. 49:1997;541-550
66. Connor T.J., Song C., Leonard B.E., Merali Z., Anisman H. An assessment of the effects of central interleukin-1beta, -2, -6, and tumor necrosis factor-alpha administration on some behavioural, neurochemical, endocrine and immune parameters in the rat. Neuroscience. 84:1998;923-933
67. Dantzer R., Bluthe R.M., Laye S., Bret-Dibat J.L., Parnet P., Kelley K.W. Cytokines and sickness behavior. Ann. NY Acad. Sci. 840:1998;586-590
68. Song C. Changes in behaviour, neurochemistry, endocrine, and immune functions caused by different routes, doses, and durations of IL-1 administration in the rat. Brain, Behav. Immun. 15:2001;185
69. Smith R.S. The macrophage theory of depression. Med. Hypotheses. 35:1991;298-306
70. Capuron L., Ravaud A., Dantzer R. Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J. Clin. Oncol. 18:2000;2143-2151
71. Capuron L., Ravaud A., Gualde N., Bosmans E., Dantzer R., Maes M., et al. Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology. 26:2001;797-808
72. Denicoff K.D., Rubinow D.R., Papa M.Z., Simpson C., Seipp C.A., Lotze M.T., et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann. Int. Med. 107:1987;293-300
73. Meyers C.A. Mood and cognitive disorders in cancer patients receiving cytokine therapy. Adv. Exp. Med. Biol. 461:1999;75-81
74. Maes M., Bosmans E., De J.R., Kenis G., Vandoolaeghe E., Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine. 9:1997;853-858
75. Maes M., Bosmans E., Suy E., Vandervorst C., DeJonckheere C., Raus J. Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1 beta and soluble interleukin-2 receptor production. Acta Psychiatr. Scand. 84:1991;379-386
76. Maes M., Stevens W., DeClerck L., Bridts C., Peeters D., Schotte C., et al. Immune disorders in depression: higher T helper/T suppressor-cytotoxic cell ratio. Acta Psychiatr. Scand. 86:1992;423-431
77. Maes M., Meltzer H.Y., Bosmans E., Bergmans R., Vandoolaeghe E., Ranjan R., et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J. Affect. Disord. 34:1995;301-309
78. Nassberger L., Traskman-Bendz L. Increased soluble interleukin-2 receptor concentrations in suicide attempters. Acta Psychiatr. Scand. 88:1993;48-52
79. Song C., Killeen A.A., Leonard B.E. Catalase, superoxide dismutase and glutathione peroxidase activity in neutrophils of sham-operated and olfactory-bulbectomised rats following chronic treatment with desipramine and lithium chloride. Neuropsychobiology. 30:1994;24-28
80. Song C., Lin A., Bonaccorso S., Heide C., Verkerk R., Kenis G., et al. The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J. Affect. Disord. 49:1998;211-219
81. Ravindran A.V., Griffiths J., Merali Z., Anisman H. Lymphocyte subsets associated with major depression and dysthymia: modification by antidepressant treatment. Psychosom. Med. 57:1995;555-563
82. Sluzewska A., Rybakowski J.K., Laciak M., Mackiewicz A., Sobieska M., Wiktorowicz K. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann. NY Acad. Sci. 762:1995;474-476
83. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiatry. 19:1995;11-38
84. Song C., Lin A., Kenis G., Bosmans E., Maes M. Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist. Schizophr. Res. 42:2000;157-164
85. Song C. Cytokines, stress, and depression: a mechanism involving corticotrophin-releasing factor. Fink G. Encyclopedia of stress. 2000;Academic Press, San Diego